English中文

Offstream
news


COVID-19 pandemic

The final results of a trial of Paxlovid conducted by Pfizer shows 89% cut of risk of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.

Sources:  Financial Times


Changes

  1. A final results of trial of Paxlovid conducted by Pfizer shows 89% cut of risl of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.
  2. A final results of trial of Paxlovid conducted by Pfizer shows 89% cut of risk of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.
  3. The final results of a trial of Paxlovid conducted by Pfizer shows 89% cut of risk of hospitalization and death in high-risk patients and is likely to work against the Omicron variant.

Related